Walgreens Boots Alliance reached a $683 million settlement with Florida to resolve claims that the pharmacy chain exacerbated an opioid epidemic in the state.

Washington reached a $518 million settlement with drug distributors McKesson Corp., AmerisourceBergen Corp. and Cardinal Health, ending a months-long trial over the companies’ alleged role in fueling the opioid epidemic in the state, the three companies announced on May 3.

Alabama reached $276 million in settlements with Johnson & Johnson, McKesson Corp. and Endo International Plc, resolving claims that the companies fueled an opioid addiction crisis, the state attorney general said.

Johnson & Johnson agreed to pay $99 million to settle claims by West Virginia that it helped fuel an opioid addiction crisis in the state, removing the company from an ongoing trial that began earlier in April.

Bayer

Bayer AG reached an $80 million settlement with Ohio to resolve environmental damage allegedly caused by polychlorinated biphenyls (PCBs) made by the company’s Monsanto business, the state attorney general said on March 24.

Teva Pharmaceutical Industries and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies. 

The Sackler family owners of Purdue Pharma LP reached a deal with nine state attorneys general to pay up to $6 billion in cash to resolve widespread litigation alleging that they fueled the U.S. opioid epidemic, bringing the OxyContin maker closer to exiting bankruptcy.

Oxycontin

The Sackler family owners of Purdue Pharma LP proposed a new and larger settlement worth up to $6 billion to resolve allegations that the OxyContin maker and the company’s owners contributed to the deadly U.S. opioid epidemic, a mediator’s report showed on February 18.

Britain’s GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in the company’s first earnings report since rejecting Unilever’s bid for GlaxoSmithKline’s consumer arm.

GSK

Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.